BACKGROUND: Alb/TGF-beta(1) transgenic mice overexpress active transforming growth factor-beta(1) (TGF-beta(1)) in the liver, leading to increased circulating levels of the cytokine and progressive renal fibrosis. This study was designed to explore if exogenous all-trans retinoic acid (tRA) prevents renal fibrosis in this animal model. METHODS: The retinoid profile in kidney and liver of wild-type and Alb/TGF-beta(1) transgenic mice was examined by high-performance liquid chromatography and slow-release pellets containing different amounts of tRA were implanted subcutaneously to treat the Alb/TGF-beta(1) transgenic mice, starting at 1 week of age; mice were sacrificed 2 weeks later. RESULTS: Kidneys of 3-week-old wild-type mice had abundant tRA, which was completely absent in kidneys of the transgenic mice. Low doses of tRA (6-10.7 mg/kg/day) failed to affect renal fibrosis although it tended to suppress the mRNA expression of some molecular markers of fibrosis and retinal dehydrogenase 2 (RALDH2), a gene encoding a key tRA-synthesising enzyme. These tendencies disappeared, mortality tended to increase and RALDH2 and connective tissue growth factor (CTGF) mRNAs significantly increased in the medium-dose group (12.7-18.8 mg/kg/day). High doses (20.1-27.4 mg/kg/day) showed even higher toxicity with increased renal fibrosis and significant mortality. CONCLUSIONS: Alb/TGF-beta(1) transgenic mice are characterised by depletion of endogenous renal tRA. Exogenous tRA dose-dependently increases mortality and kidney fibrosis, which is associated with dose-dependent regulation of renal RALDH2 and CTGF mRNA expression. Copyright 2010 S. Karger AG, Basel.
BACKGROUND:Alb/TGF-beta(1)transgenic mice overexpress active transforming growth factor-beta(1) (TGF-beta(1)) in the liver, leading to increased circulating levels of the cytokine and progressive renal fibrosis. This study was designed to explore if exogenous all-trans retinoic acid (tRA) prevents renal fibrosis in this animal model. METHODS: The retinoid profile in kidney and liver of wild-type and Alb/TGF-beta(1)transgenic mice was examined by high-performance liquid chromatography and slow-release pellets containing different amounts of tRA were implanted subcutaneously to treat the Alb/TGF-beta(1)transgenic mice, starting at 1 week of age; mice were sacrificed 2 weeks later. RESULTS: Kidneys of 3-week-old wild-type mice had abundant tRA, which was completely absent in kidneys of the transgenic mice. Low doses of tRA (6-10.7 mg/kg/day) failed to affect renal fibrosis although it tended to suppress the mRNA expression of some molecular markers of fibrosis and retinal dehydrogenase 2 (RALDH2), a gene encoding a key tRA-synthesising enzyme. These tendencies disappeared, mortality tended to increase and RALDH2 and connective tissue growth factor (CTGF) mRNAs significantly increased in the medium-dose group (12.7-18.8 mg/kg/day). High doses (20.1-27.4 mg/kg/day) showed even higher toxicity with increased renal fibrosis and significant mortality. CONCLUSIONS:Alb/TGF-beta(1)transgenic mice are characterised by depletion of endogenous renal tRA. Exogenous tRA dose-dependently increases mortality and kidney fibrosis, which is associated with dose-dependent regulation of renal RALDH2 and CTGF mRNA expression. Copyright 2010 S. Karger AG, Basel.
Authors: Peter S T Yuen; Stephen R Dunn; Takehiko Miyaji; Hideo Yasuda; Kumar Sharma; Robert A Star Journal: Am J Physiol Renal Physiol Date: 2004-02-17
Authors: Zhouhong Cao; Kathleen C Flanders; Daniel Bertolette; Lyudmila A Lyakh; Jens U Wurthner; W Tony Parks; John J Letterio; Francis W Ruscetti; Anita B Roberts Journal: Blood Date: 2002-09-12 Impact factor: 22.113
Authors: Ping La; Trish A Morgan; Stephen M Sykes; Hua Mao; Robert W Schnepp; Clark D Petersen; Xianxin Hua Journal: Oncogene Date: 2003-01-16 Impact factor: 9.867
Authors: Matthias Zenkel; Ursula Hoja; Andreas Gießl; Daniel Berner; Bettina Hohberger; Julia M Weller; Loretta König; Lisa Hübner; Thomas A Ostermann; Gabriele C Gusek-Schneider; Friedrich E Kruse; Francesca Pasutto; Ursula Schlötzer-Schrehardt Journal: Int J Mol Sci Date: 2022-05-26 Impact factor: 6.208
Authors: Yuen Fei Wong; Jeffrey B Kopp; Catherine Roberts; Peter J Scambler; Yoshifusa Abe; Alexandra C Rankin; Neelanjana Dutt; Bruce M Hendry; Qihe Xu Journal: PLoS One Date: 2011-02-04 Impact factor: 3.240